User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Economic aspects of treatment for fungal infections in cancer patients

Primary tabs

Torfs, K

Although health care expenditure has increased steadily over the past decennium, the general feeling is that resources are more limited than ever. One reason for this may be that the range of treatment options has grown so wide that the need to make rational choices has become apparent. Since treatments vary with respect to both effectiveness and cost, economic evaluations are becoming an important tool for assessing new and existing treatment strategies. The basic concepts of economic evaluation will be introduced here and the key economic questions with respect to treatment of fungal infections in cancer patients identified. Some of these concepts are explained using findings from a pilot survey carried out among participants in the symposium ''Trends in Invasive Fungal Infections - 3'' 7-9 held September, 1995, in Brussels, Belgium. The conclusion will offer recommendations for assessing economic evaluations.

Document type Communication à un colloque (Conference Paper) – Présentation orale avec comité de sélection
Access type Accès restreint
Publication date 1997
Language Anglais
Conference "Trends in Invasive Fungal Infections 3 Meeting", BRUSSELS(Belgium) (Sep, 1995)
Journal information "European Journal of Clinical Microbiology & Infectious Diseases : an international journal on pathogenesis, diagnosis, epidemiology, therapy, and prevention of infectious diseases" - Vol. 16, no. 1, p. 98-107 (1997)
Peer reviewed yes
issn 0934-9723
e-issn 1435-4373
Publisher Mmw Medizin Verlag Gmbh (Munich)
Affiliation UCL - Autre
Links
  1. Persson U, Tennvall GR, Andersson S, Tyden G, Wettermark B: Cost-effectiveness analysis of treatment with liposomal amphotericin B in organ or bone marrow transplant recipients with systemic mycoses. Pharmacoeconomics 1992, 2: 500–508.
  2. Schmitt H-J, New methods of delivery of amphotericin B. Clinical Infectious Diseases 1993, 17, Supplement 2: 501–506.
  3. De Marie S, Janknegt R, Bakker-Woudenberg I: Clinical use of liposomal and lipid-complexed amphotericin B. Journal of Antimicrobial Chemotherapy 1994, 33: 907–916.
  4. Goodman JL, Wiston DJ, Greenfeld RA, Chandrasekar PH, Fox B, Kaizer H, Shadduck RK, Shea TC, Stiff P, Friedman DJ, Powderly WG, Silber JL, Horowitz H, Lichtin A, Wolff SN, Mangan KF, Silver SM, Weisdorf D, Ho WG, Gillbert G, Buell D: A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. New England Journal of Medicine 1992, 326: 845–851.
  5. Winston DJ, Chandrasekar PH, Lazarus HM, Goodman JL, Silber JL, Horowitz H, Shadduck RK, Shea TC, Stiff P, Friedman DJ et al.: Fluconazole prophylaxis of fungal infections in patients with acute leukaemia. Annals of Internal Medicine 1993, 118: 495–503.
  6. Steward A, Powles R, Hewetson M, Antrum J, Richardson C, Metha J: Costs of antifungal prophylaxis after bone marrow transplantation. A model comparing oral fluconazole, liposomal amphoterici B and oral polyenes as prophylaxis against oropharyngeal infections. Pharmacoeconomics 1995, 8: 350–361.
  7. Williams C, Coyle D, Gray A, Hutton J, Jefferson T, Karlsson G, Kesteloot K, Uyl-de-Groot C, Wait S: European school of oncology advisory report to the Commission of the European Communities for the “Europe against Cancer Programme” cost-effectiveness in cancer care. European Journal of Cancer 1995, 31: 1410–1424.
  8. Commonwealth Department of Health, Housing and Community Services: Guidelines for the pharmaceutical industry on preparation of submissions to the Pharmaceutical Benefits Advisory Committee. Australian Government Publishing Service, Canberra, August 1992.
  9. Canadian Coordinating Office for Health Technology Assessment: Guidelines for economic evaluation of pharmaceuticals. CCOHTA, Ottawa, Canada, November 1994.
  10. Ministry of Health of Ontario: Ontario guidelines for economic analysis of pharmaceutical products. Ministry of Health, Toronto, Ontario, Canada, 1994.
  11. Clemens K, Townsend R, Luscombe F, Mauskopf J, Osterhaus J, Bobula J: Methodological and conduct principles for pharmacoeconomic research (PhRMA Pharmacoeconomics Guidelines). Pharmacoeconomic 1995, 8: 169–174
  12. Task Force on Principles for Economic Analysis of Health Care Technology: Economic analysis of health care technology. A report on principles, position paper. Annals of internal Medicine 1995, 122: 61–70.
  13. Drummond F, Stoddart G, Torrance GW: Methods for the economic evaluation of health care programmes. Oxford Medical Publications, Oxford, 1987, p. 95–104.
  14. Briggs A, Sculpher M: Sensitivity analysis in economic evaluation: a review of published studies. Health Economics 1995, 4: 355–371.
  15. Sloan FA: Introduction. In: Sloan FA (ed): Valuing health care: costs, benefits and effectiveness of pharmaceuticals and other medical technologies. Cambridge University Press, Cambridge, 1995.
Bibliographic reference Torfs, K. Economic aspects of treatment for fungal infections in cancer patients.Trends in Invasive Fungal Infections 3 Meeting (BRUSSELS(Belgium), Sep, 1995). In: European Journal of Clinical Microbiology & Infectious Diseases : an international journal on pathogenesis, diagnosis, epidemiology, therapy, and prevention of infectious diseases, Vol. 16, no. 1, p. 98-107 (1997)
Permanent URL http://hdl.handle.net/2078.1/62777